ARK Genomic Revolution ETF (ARKG)

34.58 -0.47  -1.34% BATS Jan 21, 16:58 Delayed 2m USD
View Full Chart
Price Chart

Key Stats

Net Asset Value 35.02
Discount or Premium to NAV 0.09%
Turnover Ratio 64.00%
1 Year Fund Level Flows 129.70M

Performance & Returns

  Total Return (Price) Total Return (NAV) Cat. Total Return (NAV) % Rank in Cat. (NAV)
1M 1.78% 1.81% 3.36% 84
3M 24.26% 24.24% 18.52% 7
6M 7.67% 7.68% 14.67% 96
YTD 4.56% 4.44% 2.52% 9
1Y 26.53% 26.78% 20.23% 15
3Y 27.96% 27.98% 15.66% 3
5Y 10.89% 10.75% 8.59% 24
10Y -- -- 14.80% --
15Y -- -- 11.31% --
20Y -- -- 9.78% --
As of Jan. 17, 2020. Returns for periods of 1 year and above are annualized.

Asset Allocation

Type % Net % Long % Short
Cash 0.15% 0.15% 0.00%
Stock 99.85% 99.85% 0.00%
Bond 0.00% 0.00% 0.00%
Convertible 0.00% 0.00% 0.00%
Preferred 0.00% 0.00% 0.00%
Other 0.00% 0.00% 0.00%
As of Nov. 30, 2019

Region Exposure

Americas 81.39%
North America 81.39%
Latin America 0.00%
Greater Europe 18.61%
United Kingdom 0.00%
Europe Developed 14.18%
Europe Emerging 0.00%
Africa/Middle East 4.43%
Greater Asia 0.00%
Japan 0.00%
Australasia 0.00%
Asia Developed 0.00%
Asia Emerging 0.00%
Market Classification
% Developed Markets 100.00%
% Emerging Markets 0.00%
As of Nov. 30, 2019. Region breakdown data is calculated by using the long position holdings of the portfolio.

Stock Sector Exposure

Basic Materials 0.00%
Communication Services 0.00%
Consumer Cyclical 0.00%
Consumer Defensive 0.18%
Energy 0.00%
Financial Services 0.00%
Healthcare 98.82%
Industrials 0.00%
Real Estate 0.00%
Technology 1.00%
Utilities 0.00%
As of Nov. 30, 2019

Stock Market Capitalization

Giant 1.81%
Large 11.70%
Medium 23.05%
Small 40.35%
Micro 23.09%
As of Nov. 30, 2019

Stock Style Exposure

Large Cap Value 0.00%
Large Cap Blend 4.20%
Large Cap Growth 10.34%
Mid Cap Value 0.00%
Mid Cap Blend 0.00%
Mid Cap Growth 22.32%
Small Cap Value 4.71%
Small Cap Blend 20.33%
Small Cap Growth 38.10%
As of Nov. 30, 2019
View More Holdings

Top 10 Holdings

Symbol Name % Weight Price % Chg
CRSP CRISPR Therapeutics AG 10.82% 58.12 -0.36%
ILMN Illumina Inc 9.59% 328.33 +1.11%
NVTA Invitae Corp 8.46% 18.75 -4.48%
NTLA Intellia Therapeutics Inc 7.02% 14.37 -1.78%
EDIT Editas Medicine Inc 5.92% 29.93 -2.32%
TDOC Teladoc Health Inc 4.45% 98.25 +2.77%
CGEN Compugen Ltd 3.98% -- --
IOVA Iovance Biotherapeutics Inc 3.70% 23.67 -0.86%
VCYT Veracyte Inc 3.50% 28.41 -5.77%
CLLS Cellectis SA ADR 3.35% 18.02 -1.21%
As of Nov. 30, 2019
Advertisement

Basic Info

Investment Strategy
The investment seeks long-term growth of capital. The fund is an actively-managed exchange-traded fund ("ETF") that will invest under normal circumstances primarily (at least 80% of its assets) in domestic and foreign equity securities of companies across multiple sectors, including healthcare, information technology, materials, energy and consumer discretionary, that are relevant to the fund's investment theme of the genomics revolution ("Genomics Revolution Companies"). It is non-diversified.
General
Security Type Exchange-Traded Fund
Equity Style Small Cap/Growth
Fixed Income Style --
Broad Asset Class Sector Equity
Broad Category Equity
Category Name Health
Prospectus Objective Specialty - Unaligned
Fund Owner Firm Name ARK ETF Trust
Benchmark Index
NASDAQ Health Care GR EUR 100.0%
Reports
One Page Report Download

Manager Info

Name Tenure
Catherine Wood 5.09 yrs

Net Fund Flows

1M 22.05M
3M 32.55M
6M 46.58M
YTD 129.70M
1Y 129.70M
3Y 418.54M
5Y 424.19M
10Y --
As of Dec. 31, 2019

Risk Info

Beta (5Y) 1.787
Max Drawdown (All) 37.44%
Historical Sharpe Ratio (10Y) --
Historical Sortino (All) 0.817
30-Day Rolling Volatility 19.55%
Daily Value at Risk (VaR) 1% (All) 4.97%
Monthly Value at Risk (VaR) 1% (All) 19.69%

Fundamentals

Dividend Yield TTM (1-21-20) 0%
30-Day SEC Yield --
7-Day SEC Yield --
Weighted Average PE Ratio --
Weighted Average Price to Sales Ratio 11.69
Weighted Average Price to Book Ratio 5.333
Weighted Median ROE -23.24%
Weighted Median ROA -20.70%
Forecasted Dividend Yield 0.04%
Forecasted PE Ratio 32.51
Forecasted Price to Sales Ratio 2.964
Forecasted Price to Book Ratio 4.664
Number of Holdings 38
As of Nov. 30, 2019

Growth Estimates

Forecasted 5 Yr Earnings Growth 18.31%
Forecasted Book Value Growth -6.71%
Forecasted Cash Flow Growth 49.12%
Forecasted Earnings Growth 42.15%
Forecasted Revenue Growth 14.10%
As of Nov. 30, 2019

Comparables

Edit

Attributes

Key Dates
Inception Date 10/30/2014
Termination Date
Last Annual Report Date 7/31/2019
Last Prospectus Date 11/30/2019
Attributes
Exchange Traded Share Yes
Exchange Traded Note No
Enhanced Index Fund No
Fixed Distribution Fund No
High-Net Worth Individual Fund No
Index Fund No
Inverse Fund No
Leveraged Fund No
Fund of Funds No
Currency Hedged Fund No
Synthetic Replication Fund No
Has Dividend Investment Plan No
Socially Responsible Fund No
General Availability
Available for Insurance Product No
Available for Retirement Plan No
Available for RRSP No
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.